These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17954953)

  • 1. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission.
    de Jong DJ; Bac DJ; Tan G; de Boer SY; Grabowsky IL; Jansen JB; Greinwald R; Naber TH
    Neth J Med; 2007 Oct; 65(9):339-45. PubMed ID: 17954953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.
    Hanauer S; Sandborn WJ; Persson A; Persson T
    Aliment Pharmacol Ther; 2005 Feb; 21(4):363-71. PubMed ID: 15709986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
    Sandborn WJ; Löfberg R; Feagan BG; Hanauer SB; Campieri M; Greenberg GR
    Am J Gastroenterol; 2005 Aug; 100(8):1780-7. PubMed ID: 16086715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
    Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
    Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.
    Lichtenstein GR; Bengtsson B; Hapten-White L; Rutgeerts P
    Aliment Pharmacol Ther; 2009 Mar; 29(6):643-53. PubMed ID: 19035972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
    Tromm A; Bunganič I; Tomsová E; Tulassay Z; Lukáš M; Kykal J; Bátovský M; Fixa B; Gabalec L; Safadi R; Kramm HJ; Altorjay I; Löhr H; Koutroubakis I; Bar-Meir S; Stimac D; Schäffeler E; Glasmacher C; Dilger K; Mohrbacher R; Greinwald R;
    Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
    Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
    Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
    N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.
    Gross V; Andus T; Caesar I; Bischoff SC; Lochs H; Tromm A; Schulz HJ; Bär U; Weber A; Gierend M; Ewe K; Schölmerich J
    Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):905-9. PubMed ID: 8889459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study.
    Tursi A; Giorgetti GM; Brandimarte G; Elisei W; Aiello F
    Med Sci Monit; 2006 Jun; 12(6):PI29-32. PubMed ID: 16733496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG; Sandborn WJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of budesonide with prednisolone for active Crohn's disease.
    Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
    N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budesonide for Crohn's disease.
    Seow CH; Benchimol EI; Steinhart AH; Griffiths AM; Otley AR
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):971-9. PubMed ID: 19611401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group.
    Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
    Z Gastroenterol; 1995 May; 33(5):247-50. PubMed ID: 7610691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study.
    Novacek G; Kleinberger M; Vogelsang H; Moser G; Lochs H
    Z Gastroenterol; 1995 May; 33(5):251-4. PubMed ID: 7610692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group.
    Gross V; Andus T; Ecker KW; Raedler A; Loeschke K; Plauth M; Rasenack J; Weber A; Gierend M; Ewe K; Schölmerich J
    Gut; 1998 Apr; 42(4):493-6. PubMed ID: 9616309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budesonide in the treatment of Crohn's disease: a meta-analysis.
    Papi C; Luchetti R; Gili L; Montanti S; Koch M; Capurso L
    Aliment Pharmacol Ther; 2000 Nov; 14(11):1419-28. PubMed ID: 11069312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.